Financial Comparison
Johnson & Johnson vs ELI Lilly And Company
Click a ticker to view the full analysis.
In short
ELI Lilly And Company is the more profitable of the two, keeping 31.7% of revenue as net profit against 28.5% for Johnson & Johnson. ELI Lilly And Company trades at the higher trailing P/E (39.9× vs 39.1× for Johnson & Johnson), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Johnson & Johnson and 0 for ELI Lilly And Company.
Based on filings for periods ending 27 Sept 2026 (JNJ) and 30 Jun 2026 (LLY) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. JNJ shown solid · LLY shown dashed. Not financial advice.
| Metric | JNJ | LLY |
|---|---|---|
| Price | $257.78 | $1,169.60 |
| Market Cap | $621.2B | $1.04T |
| P/E (TTM) | 39.1x | 39.9x |
| P/B | 7.3x | 30.8x |
| Beta | 0.21 | 0.45 |
| Div Yield | 2.07% | 0.59% |
| Revenue (TTM) | $94.2B | $65.2B |
| Net Income | $26.8B | $20.6B |
| Gross Margin | 67.9% | — |
| Risk Flags | 1 flag | — |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.